Equity (Details Textual) |
1 Months Ended | 3 Months Ended | 12 Months Ended | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jul. 11, 2018
ILS (₪)
shares
|
Mar. 01, 2018
₪ / shares
shares
|
Dec. 26, 2017
ILS (₪)
shares
|
Dec. 26, 2017
USD ($)
shares
|
Nov. 09, 2017
ILS (₪)
₪ / shares
shares
|
Nov. 08, 2017
ILS (₪)
₪ / shares
shares
|
Jun. 09, 2016
ILS (₪)
₪ / shares
shares
|
Feb. 02, 2016
ILS (₪)
₪ / shares
shares
|
Jul. 26, 2018 |
Apr. 16, 2018
₪ / shares
|
Jan. 18, 2018
shares
|
Feb. 12, 2017
ILS (₪)
₪ / shares
shares
|
Nov. 17, 2016 |
Jun. 30, 2017
ILS (₪)
share
₪ / shares
shares
|
Dec. 31, 2018
ILS (₪)
shares
|
Dec. 31, 2018
USD ($)
shares
|
Dec. 31, 2017
shares
|
Jul. 28, 2016
ILS (₪)
share
shares
|
|
| Equity (Textual) | ||||||||||||||||||
| Shares issued | 190,735,668 | 190,735,668 | 166,816,328 | 1,067,916 | ||||||||||||||
| Shares held by the Company | 920,461 | 920,461 | ||||||||||||||||
| Ordinary shares holders right to vote and participate shareholder meetings description | The ordinary shares confer on their holders the right to vote and participate in shareholder meetings (with one vote for each share), the right to receive profits and the right to participate in surplus assets on liquidation of the Company. | The ordinary shares confer on their holders the right to vote and participate in shareholder meetings (with one vote for each share), the right to receive profits and the right to participate in surplus assets on liquidation of the Company. | ||||||||||||||||
| Capital raise amount | ₪ | ₪ 11,800,000 | ₪ 8,200,000 | ₪ 7,200,000 | |||||||||||||||
| Issuance costs | ₪ 684,000 | ₪ 643,000 | ₪ 404,000 | ₪ 6,383,000 | $ 1,703,000 | |||||||||||||
| Acquired equipment and clean rooms | ₪ | ₪ 1,849,000 | |||||||||||||||||
| Total consideration amount paid in cash | ₪ | ₪ 1,197,000 | |||||||||||||||||
| Total consideration amount paid in shares | share | 1,067,916 | |||||||||||||||||
| Repaid cash over the term | ₪ | ₪ 525,000 | |||||||||||||||||
| Ordinary shares and warrants description | Pursuant to the reverse split each 3 ordinary shares of NIS 0.01 par value were converted into one share of NIS 0.03 par value of the Company. Additionally, according to the share option plan of the Company, every 3 unlisted options that were allocated through private offers to directors, employees, consultants and officers under the option plan are exercisable into one ordinary share of the Company of NIS 0.03 par value. No change took place in the exercise price of the options, as above; however, the total exercise price for one share of NIS 0.03 par value will be the former exercise price for one share of NIS 0.01 par value multiplied by 3. Further, according to the terms and conditions of the marketable warrants of the Company, each 3 marketable warrants that the Company issued are exercisable into one ordinary share of the Company of NIS 0.03 par value. There will be no change in the exercise price of those warrants; however, the total exercise price for one share of NIS 0.03 par value will be the former exercise price for one share of NIS 0.01 par value multiplied by 3. Following the reverse split, the Company retrospectively reflected the change in the share capital of the Company for all periods presented. Unless otherwise indicated, all of the share numbers, losses per share, share prices, options and warrants in these financial statements have been adjusted, on a retroactive basis, to reflect this 1 to 3 reverse share split. | |||||||||||||||||
| Meitav Purchase Agreement [Member] | ||||||||||||||||||
| Equity (Textual) | ||||||||||||||||||
| Ordinary shares of par value | ₪ / shares | ₪ 40 | |||||||||||||||||
| Warrants exercisable into ordinary shares | 11,900,000 | |||||||||||||||||
| Exercise period | 5 years | |||||||||||||||||
| Meitav Purchase Agreement [Member] | Tranches One [Member] | ||||||||||||||||||
| Equity (Textual) | ||||||||||||||||||
| Shares issued | 11,900,000 | 11,900,000 | 9,500,000 | |||||||||||||||
| Gross proceeds of debenture | ₪ 4,760,000 | $ 1,384,824 | ||||||||||||||||
| Ordinary shares purchase price | ₪ | ₪ 3,800,000 | |||||||||||||||||
| Meitav Purchase Agreement [Member] | Tranches Two [Member] | ||||||||||||||||||
| Equity (Textual) | ||||||||||||||||||
| Shares issued | 11,900,000 | 11,900,000 | 2,400,000 | |||||||||||||||
| Gross proceeds of debenture | ₪ 4,760,000 | $ 1,384,824 | ||||||||||||||||
| Percentage of closing securities purchase agreement | 20.00% | |||||||||||||||||
| Ordinary shares purchase price | ₪ | ₪ 960,000 | |||||||||||||||||
| Meitav Purchase Agreement [Member] | Tranches Three [Member] | ||||||||||||||||||
| Equity (Textual) | ||||||||||||||||||
| Warrants to purchase of ordinary shares | 11,900,000 | 11,900,000 | ||||||||||||||||
| Sagy Purchase Agreement [Member] | ||||||||||||||||||
| Equity (Textual) | ||||||||||||||||||
| Ordinary shares of par value | ₪ / shares | ₪ 40 | |||||||||||||||||
| Warrants exercisable into ordinary shares | 9,300,000 | |||||||||||||||||
| Exercise period | 5 years | |||||||||||||||||
| Sagy Purchase Agreement [Member] | Tranches One [Member] | ||||||||||||||||||
| Equity (Textual) | ||||||||||||||||||
| Shares issued | 9,300,000 | |||||||||||||||||
| Warrants exercisable into ordinary shares | 9,300,000 | 9,300,000 | ||||||||||||||||
| Gross proceeds of debenture | ₪ 3,720,000 | $ 1,054,122 | ||||||||||||||||
| Ordinary shares purchase price | ₪ | ₪ 3,700,000 | |||||||||||||||||
| Sagy Purchase Agreement [Member] | Tranches Two [Member] | ||||||||||||||||||
| Equity (Textual) | ||||||||||||||||||
| Warrants to purchase of ordinary shares | 9,300,000 | 9,300,000 | ||||||||||||||||
| Security Purchase Agreement [Member] | ||||||||||||||||||
| Equity (Textual) | ||||||||||||||||||
| Shares issued | 4,344,340 | |||||||||||||||||
| Ordinary shares and warrants description | Pursuant to which the Company issued on July 31, 2018, in a private placement, 11,125,000 ordinary shares for an aggregate purchase price of NIS 4,561,250 (approximately $1.25 million). | The Company signed Security Purchase Agreements for the purchase and sale, in a private placement, of an aggregate of 4,344,340 ordinary shares for an aggregate of NIS 2.2 million to the following three investors as follows: (i) Alpha entered into a Security Purchase Agreement for the purchase of 1,275,340 ordinary shares for NIS 638 thousand; (ii) Ami Sagi entered into a Security Purchase Agreement for the purchase of 2,046,000 ordinary shares for NIS 1 million; and (iii) Docor International BV entered into a Security Purchase Agreement for the purchase of 1,023,000 ordinary shares for NIS 511 thousand. Closing occurred on January 25, 2018. | ||||||||||||||||
| Ordinary Shares [Member] | ||||||||||||||||||
| Equity (Textual) | ||||||||||||||||||
| Shares issued | 250,000,000 | 11,267,833 | 5,745,903 | |||||||||||||||
| Shares held by the Company | 21,200 | 750,000,000 | ||||||||||||||||
| Ordinary shares of par value | ₪ / shares | ₪ 0.03 | |||||||||||||||||
| Warrants to purchase of ordinary shares | 1,060,000 | |||||||||||||||||
| Share based compensation | ₪ | ₪ 492,000 | |||||||||||||||||
| Ordinary Shares [Member] | January 31, 2018 [Member] | ||||||||||||||||||
| Equity (Textual) | ||||||||||||||||||
| Shares issued | 50 | 50 | ||||||||||||||||
| Series I Warrants [Member] | ||||||||||||||||||
| Equity (Textual) | ||||||||||||||||||
| Number of warrants | 12,930,505 | |||||||||||||||||
| Warrants exercisable into ordinary shares | 4,310,168 | |||||||||||||||||
| Warrant to purchase of ordinary shares exercise price | ₪ / shares | ₪ 0.80 | |||||||||||||||||
| Exercise period | 3 years | |||||||||||||||||
| Series I Warrants [Member] | Israeli Broker [Member] | ||||||||||||||||||
| Equity (Textual) | ||||||||||||||||||
| Number of warrants | 814,520 | |||||||||||||||||
| Warrants exercisable into ordinary shares | 271,507 | |||||||||||||||||
| Warrant to purchase of ordinary shares exercise price | ₪ / shares | ₪ 0.80 | ₪ 0.4 | ||||||||||||||||
| Exercise period | 3 years | |||||||||||||||||
| Series J Warrants [Member] | ||||||||||||||||||
| Equity (Textual) | ||||||||||||||||||
| Number of warrants | 8,618,855 | |||||||||||||||||
| Warrants exercisable into ordinary shares | 2,872,952 | |||||||||||||||||
| Warrant to purchase of ordinary shares exercise price | ₪ / shares | ₪ 0.575 | |||||||||||||||||
| Warrants expired | On July 31, 2016, 8,618,855 Series J warrants expired. | |||||||||||||||||
| Series K Warrants [Member] | ||||||||||||||||||
| Equity (Textual) | ||||||||||||||||||
| Number of warrants | 33,803,500 | |||||||||||||||||
| Warrants exercisable into ordinary shares | 11,267,833 | |||||||||||||||||
| Warrant to purchase of ordinary shares exercise price | ₪ / shares | ₪ 0.60 | |||||||||||||||||
| Exercise period | 3 years | |||||||||||||||||
| Series K Warrants [Member] | Israeli Broker [Member] | ||||||||||||||||||
| Equity (Textual) | ||||||||||||||||||
| Number of warrants | 2,728,000 | |||||||||||||||||
| Warrants exercisable into ordinary shares | 909,333 | |||||||||||||||||
| Warrant to purchase of ordinary shares exercise price | ₪ / shares | ₪ 0.60 | ₪ 0.4 | ||||||||||||||||
| Exercise period | 3 years | |||||||||||||||||
| Series L Warrants [Member] | ||||||||||||||||||
| Equity (Textual) | ||||||||||||||||||
| Shares issued | 21,152,000 | |||||||||||||||||
| Number of warrants | 10,576,000 | 10,055,464 | ||||||||||||||||
| Warrants exercisable into ordinary shares | 10,576,000 | 10,055,464 | ||||||||||||||||
| Warrant to purchase of ordinary shares exercise price | ₪ / shares | ₪ 0.36 | ₪ 0.36 | ||||||||||||||||
| Total consideration amount paid in cash | ₪ | ₪ 3,618,000 | |||||||||||||||||
| Total consideration amount paid in shares | share | 1,461,936 | |||||||||||||||||
| Series L Warrants [Member] | Israeli Broker [Member] | ||||||||||||||||||
| Equity (Textual) | ||||||||||||||||||
| Number of warrants | 941,400 | |||||||||||||||||
| Warrants exercisable into ordinary shares | 941,400 | |||||||||||||||||
| Warrant to purchase of ordinary shares exercise price | ₪ / shares | ₪ 0.36 | |||||||||||||||||
| Warrants expired | Series L warrants that were not exercised expired on June 14, 2017. | |||||||||||||||||